Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Dose Attenuated Chemotherapy in Patients With Lung Cancer and Age > 70 and/or Comorbidities

NCT05800587 is registered in ClinicalTrials.gov with Fox Chase Cancer Center as lead sponsor.

NCT NCT05800587
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05800587 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Dose Attenuated Chemotherapy in Patients With Lung Cancer and Age > 70 and/or Comorbidities
Lead sponsor
Fox Chase Cancer Center
Phase
Phase 2
Overall status
Recruiting
Start date
February 22, 2023
Completion date
August 1, 2029
Enrollment
280 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer, non small cell lung cancer, small-cell lung cancer